Skip to content
Screener

Gyre Therapeutics, Inc. GYRE Free cash flow margin

Free cash flow margin at other companies

Eli Lilly logo
Eli LillyLLY
22.8%+13.7pp
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
-59.8%-29.6pp
Theravance Biopharma logo
Theravance BiopharmaTBPH
221.9%+206pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-75%-30.5pp
LQD
Liquidia CorporationLQDA
-150.7%-64.4pp
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-61.1%-26.8pp

Other financials

Income statement

See full
Revenue$29.1M-2.1%
Gross profit$26.9M-5.9%
Operating income-$14.4M-541%
Net income-$11.7M-471%
EPS (diluted)-$0.12-300%

Balance sheet

See full
Cash & equivalents$43.3M+18.6%
Total debt$3.4M+145%
Total equity$107.9M+17.3%
Total assets$199.3M+30.5%

Cash flow

See full
Operating cash flow-$16.7M-124%
CapEx$262.0K-21.8%
Free cash flow-$17.0M-118%

Valuation

See full
Market cap$743.63M+16.0%
Enterprise value$703.76M+16.2%
P/S6.2×+0.1×

Profitability

See full
Gross margin94.3%-1.7pp
Operating margin-14%-18.7pp
Net margin-13.4%-15.1pp

Returns & leverage

See full
Return on equity-16%-18.3pp
Debt / equity0.0×
Current ratio4.3×-1.1×

Where this comes from

Calculated from Gyre Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026. Open the filing →

Filed
Aug 7, 2026, 5:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-340448

FAQ

What is Gyre Therapeutics, Inc.'s free cash flow margin?
Gyre Therapeutics, Inc. (GYRE) reported free cash flow margin of -5.1% in Q2 2026.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.

Ask your AI about Gyre Therapeutics, Inc.'s free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude